Browsing Tag
EPKINLY
3 posts
Can Epcoritamab plus R2 become the new second-line standard in follicular lymphoma after Genmab’s Phase 3 success?
Genmab’s Epcoritamab plus R2 combo cut FL relapse risk by 79% in Phase 3. Find out why this bispecific therapy may reshape second-line treatment.
FDA authorizes breakthrough Epkinly regimen from AbbVie for relapsed or refractory follicular lymphoma
Discover how AbbVie’s newly approved Epkinly regimen with rituximab and lenalidomide is redefining treatment for relapsed or refractory follicular lymphoma.
Genmab gets EPKINLY FDA approval for diffuse large B-cell lymphoma
Danish biotech company Genmab has secured accelerated approval for EPKINLY (epcoritamab-bysp) from the US Food and Drug Administration…